Long DOAC + Short DOAC
ApprovedCompleted 1 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Venous Thrombosis
Conditions
Venous Thrombosis, Neoplasms, Anticoagulants
Trial Timeline
Feb 18, 2021 → Dec 31, 2024
NCT ID
NCT04724460About Long DOAC + Short DOAC
Long DOAC + Short DOAC is a approved stage product being developed by Bayer for Venous Thrombosis. The current trial status is completed. This product is registered under clinical trial identifier NCT04724460. Target conditions include Venous Thrombosis, Neoplasms, Anticoagulants.
What happened to similar drugs?
5 of 20 similar drugs in Venous Thrombosis were approved
Approved (5) Terminated (3) Active (13)
Hype Score Breakdown
Clinical
20
Activity
8
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04724460 | Approved | Completed |
Competing Products
20 competing products in Venous Thrombosis